Key result
Sodium-glucose co-transporter 2 inhibitors reduced the risk of major cardiovascular events and heart failure hospitalization compared with placebo in HFpEF.
Why the study?
Despite a lack of effective pharmacological treatments for HFpEF, recent studies suggested SGLT2Is may offer potential benefits in reducing cardiovascular events.
Do sodium-glucose co-transporter 2 inhibitors reduce major adverse cardiovascular events and hospitalisation for heart failure in patients with heart failure with preserved ejection fraction?
Meta-Analysis (n=12,436)
Do sodium-glucose co-transporter 2 inhibitors reduce major adverse cardiovascular events and hospitalisation for heart failure in patients with heart failure with preserved ejection fraction?
SGLT2 inhibitors significantly reduce the risk of major adverse cardiovascular events and heart failure hospitalizations in patients with HFpEF.
Answers are grounded in this paper and cite their sources.
Supports SGLT2 inhibitor use in HFpEF; reinforces consensus and addresses prior therapeutic gap.
Background: Heart failure with preserved ejection fraction (HFpEF) is a prevalent and challenging cardiovascular condition associated with high morbidity and mortality. Despite the lack of effective pharmacological treatments, recent studies have suggested that sodium-glucose co-transporter 2 inhibitors (SGLT2Is) may offer potential benefits in reducing cardiovascular events in HFpEF patients. The aim of this systematic review and meta-analysis is to assess the efficacy of SGLT2Is in reducing cardiovascular outcomes in individuals with HFpEF. Methods: A comprehensive literature search was conducted across PubMed, Cochrane Library, Embase, and clinical trial registries for studies published up to October 2024. Randomised controlled trials (RCTs) that investigated the use of SGLT2Is in patients with HFpEF and reported on major cardiovascular outcomes were included. Data from eligible studies were pooled to calculate risk ratios (RR) and 95% CIs for the primary outcomes, including major adverse cardiovascular events (MACE) and hospitalisation for heart failure (HHF). Results: Fifteen RCTs involving 12,436 patients with HFpEF were included in the meta-analysis. Treatment with SGLT2Is reduced the risk of MACE (RR=0.79, 95% CI [0.70-0.89]) and HHF (RR=0.72, 95% CI [0.65-0.87]) compared with placebo. Secondary analyses demonstrated reductions in cardiovascular mortality (RR=0.84, 95% CI [0.75-0.95]) and improvements in health-related quality of life as assessed by Kansas City Cardiomyopathy Questionnaire scores. Conclusion: SGLT2Is significantly reduce cardiovascular events, including HHF and MACE, in patients with HFpEF. These findings support the growing evidence for the use of SGLT2Is as a promising therapeutic option in this high-risk patient population.
No takes yet. Share an insight, caveat, or question.
Hussein et al. (2026) conducted a meta-analysis in Heart failure with preserved ejection fraction (HFpEF) (n=12,436). Sodium-glucose co-transporter 2 inhibitors (SGLT2Is) vs. placebo was evaluated on Major adverse cardiovascular events (MACE) (RR 0.79, 95% CI 0.70-0.89). Sodium-glucose co-transporter 2 inhibitors reduced the risk of major cardiovascular events and heart failure hospitalization compared with placebo in HFpEF.
Synapse has enriched 10 related papers. Consider them for comparative context: